Ophthopedia’s Post

New article in Drugs in Context Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences bernardo rossini, Nicola Cecchi, Felice Clemente, Maria Rosaria De Paolis, Stefan Hohaus, Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Giovanna Palumbo, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga, Attilio Guarini This article provides evidence from real-world practice in the treatment of Castleman disease with siltuximab, focusing on the idiopathic multicentric diagnostic work-up and treatment administration in patients with complex disease entering differential diagnosis with Castleman disease or concomitant diseases. #drugsincontext #hematology #treatment #monoclonalantibodies #realworldevidence https://lnkd.in/dmN-VQYZ

The use of transdermal preparations of Sinomenium acutum (SA) in treating rheumatoid arthritis (RA) is gaining attention, especially when used alongside disease-modifying antirheumatic drugs (DMARDs). A meta-analysis published in Chinese Medicine and Culture reviewed six randomized controlled trials involving 436 patients and suggests that SA combined with DMARDs may provide greater clinical efficacy, including reduced pain and improved inflammation markers like erythrocyte sedimentation rate and C-reactive protein. While these findings are promising, further high-quality research is needed to verify these results and explore the safety of SA transdermal therapy. This study underscores the potential of integrating traditional Chinese medicine with contemporary RA treatments. Explore the detailed findings of this study in Chinese Medicine and Culture and its implications for RA treatment: https://ow.ly/LSU550TlJps #SinomeniumAcutum #RheumatoidArthritis #DMARDs #MedicalResearch #TraditionalChineseMedicine #HerbalTherapy #Inflammation #ChronicDisease #ChineseMedicineAndCulture

Our real-world evidence experts have reviewed the latest decision on GAMMAGARD LIQUID. Start reading "FDA Approves GAMMAGARD LIQUID Based on Safety Data From an RWE Study" - https://lnkd.in/et3NiwzY -- Background: The recent approval of GAMMAGARD LIQUID by the FDA for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), is a great example of the power of RWE to inform regulatory decision-making. The approval was based on data from a single-arm Phase III study and a large observational, retrospective comparative safety study assessing the off-label use of GAMMAGARD LIQUID and other intravenous immunoglobulin products for the treatment of patients with CIDP. #RWE #realworldevidence #rwd #realworlddata

Explore Our Candidates: MIRA1a & Ketamir 💡 Introducing MIRA-55 - Our Key Candidate If approved by the FDA, our initial drug candidate, MIRA-55, may be a significant advancement in treating #neuropsychiatric, #inflammatory, and #neurologic diseases and disorders. MIRA1a unlocks the therapeutic potential of #marijuana with a single molecule that targets binding sites of the body’s #endocannabinoid system. 💡 Introducing Ketamir - Our Unique Ketamine Analog Our secondary drug candidate is a unique, patent-pending novel #ketamine #analog that is predicted to have good gastrointestinal bioavailability. It is currently under investigation to potentially orally deliver ultra-rapid antidepressant effects, providing hope for individuals battling #treatmentresistantdepression (TRD) and #majordepressivedisorder with suicidal ideation (MDSI). 🌐 Learn more on our website: https://lnkd.in/dUWmX3Pc #DrugDevelopment #Innovation #MIRA1a #Ketamir #MedicalAdvancements #PreClinical #MIRAingNeuroscientificBreakthroughs

Aneurysmal subarachnoid haemorrhage (aSAH) is an uncommon but ominous type of stroke that occurs at a younger age and has high mortality rates. While the current surgical treatments for aSAH have a risk of permanent disability and death that often outweighs the potential benefits, a non-invasive pharmacotherapy modality would be very beneficial. Shahab Abtahi and Olaf Klungel from our Division, together with other colleagues conducted study where they applied a 'drug wide association study' approach using real-world data from Wales and found 5 drugs that potentially might lower the risk of aSAH, including lisinopril, amlodipine, simvastatin, metformin, and tamsulosin. You can read more about their findings below https://lnkd.in/daraGs6k

Check out our new study about multiple myeloma treatment patterns published in the European Journal of Haematology: https://lnkd.in/gVyDnGtR In this multi-country study conducted for GSK, our colleagues Evi Zhuleku, Moritz Lehne and Marco Ghiani used data from claims and medical charts to investigate real-world treatment patterns in third-line relapsed/refractory multiple myeloma (RRMM) patients in Germany, Italy, the UK, France and Spain. The study provides a comprehensive overview of the evolving RRMM treatment landscape in key European countries. #Cytel #RWE #MultipleMyeloma #TreatmentPatterns

In response to tremendous medical need and unprecedented market demand, Vivani is accelerating the development of two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide).   These implants have the potential to transform and advance the adoption of GLP-1 therapy by directly addressing the limitations of currently marketed products, which include poor medication adherence and tolerability.   Read more here: https://lnkd.in/ep5tZ_fE.   #WeightLossDrugs #Semaglutide

The Feb 8 issue of #NEJM just landed in my mailbox. I wrote the editorial "Psoriasis - More Progress but more questions" I discuss the latest stunning advance, Johnson & Johnson's phase 2 trial of an ORAL IL-23 receptor antagonist PEPTIDE for #psoriasis. I make the following points: 1. JNJ-77242113 achieved #PASI90 in 60% of patients - similar to some of our best biologics but in a pill! 2. General well tolerated but two #infections (SAEs COVID and an infected cyst) + and one suicide attempt need to be further evaluated in larger trials 3. #Obesity appeared to impact efficacy and having to take it twice a day on an empty stomach may diminish efficacy in real world settings 4. The progress made in developing drugs that clear psoriasis is tempered by a relative lack of progress in understanding the effect of the treatments on preventing #psoriaticarthritis #diabetes & #cardiovasculardisease To further advance the science and management of psoriasis the next generation of trials will need to have a #pragmatic, randomized design, active comparators, larger sample sizes and longer durations to determine which treatments, if any, restore not only the skin to normal but also the patient's overall health and lifespan. Only then will the full promise of these advances be realized.

Day 6/50 :- AMIODARONE *Adverse Effects of Amiodarone* The – Thyroid ( both hypo and hyperthyroidism ) Periphery of – Peripheral Neuropathy My- Myocardial Depression Lung – Lung fibrosis Liver and - Liver toxicity ( including cirrhosis) Cornea is – Corneal micro deposit Photosensitive - Photosensitivity • Longest acting (t1/2 = 3-8 weeks) anti-arrhythmic drug. • It possesses action of all classes of antiarrhythmic drugs (Na+ channel blockade non-competitive, β blockade, K+ channel blockade and Ca2+ channel blockade). • It carries less chances of causing torsades despite prolongation of QT interval. • It contains iodine (approx. 37.5%) and can result in hyperthyroidism (similar drug dronaderone do not contain iodine). • Dronedarone is a similar drug but lacks iodine and thus adverse effects on thyroid are not seen. • Amiodarone is indicated for the treatment of refractory VT or VF, particularly in the setting of acute ischemia. • Also safe to use in individuals with cardiomyopathy and atrial fibrillation, to maintain normal sinus rhythm. • It can be used for the prophylaxis of almost all arrhythmias except torsades de’pointes. • Dose :- 200mg thrice daily for 4 weeks, 200 mg daily thereafter #Pharmacology #CliMedResearchSolution #Climed

We at SAIA are excited to share the latest research published in the Indian Journal of Gastroenterology! Read here: https://lnkd.in/gc3EcDbP Exploring Acute Severe Ulcerative Colitis (ASUC): ASUC, occurring in one-fifth of UC patients, poses life-threatening risks with a mortality rate of up to 1%. Despite its severity, there's a lack of validated clinical scoring systems for ASUC. Intravenous corticosteroids are vital for management, yet a third of patients are steroid refractory, necessitating colectomy or salvage therapy. Predictors of non-response are limited, emphasizing the need for clearer outcome measures. While infliximab and cyclosporine are effective salvage therapies, treatment failure rates persist. Thus, there's a crucial need to explore alternative options, especially for prior infliximab-exposed patients. This could involve rapid-action small molecules or sequential therapies with slow-onset biologics post-"bridging" with cyclosporine. Our article delves into evidence-based practices and identifies knowledge gaps in ASUC management. Stay informed to navigate this critical condition effectively. #UlcerativeColitis #ASUC #HealthcareInsights #SouthAsianIBDAlliance #SAIA #IBDesis #ulcerativecolitis #colectomy #jpouch #fistula #Crohns #research #patientadvocacy #SouthAsianIBD #desi #logkyakahenge